Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Mauro

Showing results (121-130 of 136) with videos related to

Pageof 14
Sort By:
Leukemia Research|December 10, 2013
Fludarabine plus alemtuzumab (FA) front-line treatment in young patients with chronic lymphocytic leukemia (CLL) and an adverse biologic profileFrancesca R Mauro, Stefano Molica, Luca Laurenti, et al.
British Journal of Haematology|April 4, 2018
In chronic lymphocytic leukaemia with complex karyotype, major structural abnormalities identify a subset of patients with inferior outcome and distinct biological characteristicsGian Matteo Rigolin, Elena Saccenti, Emanuele Guardalben, et al.
Hematological Oncology|March 19, 2021
Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working GroupGian Matteo Rigolin, Francesco Cavazzini, Alfonso Piciocchi, et al.
Haematologica|November 2, 2020
High rate of MRD-responses in young and fit patients with IGHV mutated chronic lymphocytic leukemia treated with front-line fludarabine, cyclophosphamide, and intensified dose of ofatumumab (FCO2)Francesca R Mauro, Stefano Molica, Stefano Soddu, et al.
Leukemia|December 10, 2015
A progression-risk score to predict treatment-free survival for early stage chronic lymphocytic leukemia patientsM Gentile, T D Shanafelt, G Cutrona, et al.
Leukemia|June 25, 2025
Richter transformation in diffuse large B-cell lymphoma in patients with chronic lymphocytic leukemia receiving ibrutinib: risk factors and outcomesSara Pepe, Candida Vitale, Diana Giannarelli, et al.
Blood|August 16, 2015
Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemiaDavide Rossi, Lodovico Terzi-di-Bergamo, Lorenzo De Paoli, et al.
European Journal of Cancer (Oxford, England : 1990)|April 30, 2016
Combination of bendamustine and rituximab as front-line therapy for patients with chronic lymphocytic leukaemia: multicenter, retrospective clinical practice experience with 279 cases outside of controlled clinical trialsMassimo Gentile, Katja Zirlik, Stefania Ciolli, et al.
Hemasphere|July 16, 2024
CD49d expression is included in a revised 4-factor model predicting outcome in patients with chronic lymphocytic leukemia treated with ibrutinib: A multicenter real-world experienceRiccardo Bomben, Antonella Zucchetto, Roberta Laureana, et al.
Blood|April 9, 2020
International prognostic score for asymptomatic early-stage chronic lymphocytic leukemiaAdalgisa Condoluci, Lodovico Terzi di Bergamo, Petra Langerbeins, et al.
Pageof 14

Showing results (121-130 of 136) with videos related to

Sort By:
Pageof 14
Leukemia Research|December 10, 2013
Fludarabine plus alemtuzumab (FA) front-line treatment in young patients with chronic lymphocytic leukemia (CLL) and an adverse biologic profileFrancesca R Mauro, Stefano Molica, Luca Laurenti, et al.
British Journal of Haematology|April 4, 2018
In chronic lymphocytic leukaemia with complex karyotype, major structural abnormalities identify a subset of patients with inferior outcome and distinct biological characteristicsGian Matteo Rigolin, Elena Saccenti, Emanuele Guardalben, et al.
Hematological Oncology|March 19, 2021
Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working GroupGian Matteo Rigolin, Francesco Cavazzini, Alfonso Piciocchi, et al.
Haematologica|November 2, 2020
High rate of MRD-responses in young and fit patients with IGHV mutated chronic lymphocytic leukemia treated with front-line fludarabine, cyclophosphamide, and intensified dose of ofatumumab (FCO2)Francesca R Mauro, Stefano Molica, Stefano Soddu, et al.
Leukemia|December 10, 2015
A progression-risk score to predict treatment-free survival for early stage chronic lymphocytic leukemia patientsM Gentile, T D Shanafelt, G Cutrona, et al.
Leukemia|June 25, 2025
Richter transformation in diffuse large B-cell lymphoma in patients with chronic lymphocytic leukemia receiving ibrutinib: risk factors and outcomesSara Pepe, Candida Vitale, Diana Giannarelli, et al.
Blood|August 16, 2015
Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemiaDavide Rossi, Lodovico Terzi-di-Bergamo, Lorenzo De Paoli, et al.
European Journal of Cancer (Oxford, England : 1990)|April 30, 2016
Combination of bendamustine and rituximab as front-line therapy for patients with chronic lymphocytic leukaemia: multicenter, retrospective clinical practice experience with 279 cases outside of controlled clinical trialsMassimo Gentile, Katja Zirlik, Stefania Ciolli, et al.
Hemasphere|July 16, 2024
CD49d expression is included in a revised 4-factor model predicting outcome in patients with chronic lymphocytic leukemia treated with ibrutinib: A multicenter real-world experienceRiccardo Bomben, Antonella Zucchetto, Roberta Laureana, et al.
Blood|April 9, 2020
International prognostic score for asymptomatic early-stage chronic lymphocytic leukemiaAdalgisa Condoluci, Lodovico Terzi di Bergamo, Petra Langerbeins, et al.
Pageof 14